REVO

meerecompany’s Revo-i, South Korea’s first domestically developed endoscopic surgical robot, is gaining significant momentum in the global market.

While robotic surgery has reached saturation in the U.S. and Europe, emerging markets are showing rapid growth driven by aging populations and the modernization of healthcare systems.

Endoscopic Surgical Robots Now Accounts for 70%,

Leading the Fast-Growing Surgical Robot Market

According to global research firm “Precedence Research,” the global surgical robot market is expected to reach USD 10.8 billion in 2024 and grow at an average annual growth rate of 16%, expanding to USD 22.9 billion by 2029.

Notably, endoscopic surgical robots represent 74% of the market, representing approximately USD 16.9 billion.

While North America, Europe, and advanced East Asian countries remain the key players, emerging economies are gaining attention for their growth potential. Rapid improvements in medical infrastructure and supportive government policies are fueling adoption across these regions.

In particular, high-cost systems are often less viable in emerging markets, making cost-effective solutions like Revo-i a competitive choice.

Revo-i has already been exported to Uzbekistan, Russia, Mongolia, Morocco, and Paraguay.

Among them, Russia represents the largest market in Central and Eastern Europe. Given its vast territory and large population, the modernization of its medical system and innovations in digital healthcare are essential, leading to increased adoption of robotic surgery.

Revo-i is also expanding its footprint in Southeast Asia, having recently obtained certifications in both Vietnam and the Philippines. As robotic surgery becomes more widespread in these countries, new competitive dynamics are emerging.

In Latin America and North Africa, Revo-i establishing strategic footholds. The robot’s cost-efficiency continues to be a major advantage, accelerating its adoption in these regions.

Uzbekistan: A Model for National Healthcare Innovation

Uzbekistan, the first country to adopt Revo-i, is now regarded as a benchmark success case. The system was initially introduced at a private hospital in Tashkent in 2021. With strong backing from both the hospital and the government, robotic surgery has gained traction.

In 2023, a second unit was installed at a private hospital in Samarkand, followed by a third unit in 2024 at the National Urology Center, a public institution.

Revo-i has even contributed to shaping national healthcare policy in Uzbekistan. Its adoption helped initiate insurance coverage for robotic surgery, which is gradually expanding to include patients with severe illnesses and other prioritized cases.

Although robotic surgery remains less accessible than open or laparoscopic procedures due to higher costs, increased government support is expected to drive broader adoption in the near future.

[Photo] meerecompany HQ training team member conducting on-site Revo-i training

Revo-i's global market expansion has been fueled in part by the strong trust in Korean medical devices. Emerging markets, in particular, highly value the technological sophistication and safety of Korean-made equipment—factors that have played a key role in Revo-i's swift market adoption.

Localization efforts have also been essential. meerecompany has gone beyond simply supplying equipment, offering robust local training and maintenance support to build long-term partnerships with hospitals and medical professionals. This approach is embodied in “Revo Care,” a value-added service model that provides customized, hands-on support tailored to each market.

Lastly, price competitiveness remains a major advantage. While robotic surgery is becoming essential in many surgical fields, high upfront costs still pose a barrier. In this context, Revo-i's affordability and lower maintenance costs have captured the attention of both surgeons and hospital administrators.

A meerecompany representative stated, “As the global surgical robot market grows rapidly in emerging regions, Revo-i is not just an alternative—it’s setting a new standard with differentiated value and strategy.”

They added, “Revo-i’s global expansion will only accelerate, so we will continue to strengthen our R&D efforts and advance market-specific strategies to support sustainable growth.”

This article was published by the Korean media Dailymedi on April 7, 2025.

Link: https://www.dailymedi.com/news/news_view.php?wr_id=923473